ALEC.US Alector Inc

Healthcare Biotechnology USA Stocks
2.54 USD
Close of Nov 13, 2026
1.09 2.84
Market cap
USD 378M
P/E
6.9x
P/B
3.13x
ROE
90.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ALEC.US undervalued?

Graham number
Price2.54
Graham value2.60
Discount2.3%

ALEC.US trades 2.3% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alector Inc fundamental analysis

No fundamental analysis for Alector Inc yet.

Alector Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alector Inc

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical devel…

Full company profile